Rivaroxabanisanorallybioavailableoxazolidonederivativethatactsasanantithrombotic/anticoagulant,reversIBLyinhibitingfactorXa.RivaroxabandirectlybindstotheS1andS4pocketsoffactorXaandinhibitsbothfreeandclot-boundforms.Invitromodelsindicatethatrivaroxabanmayalsoexertinhibitoryeffectsduringtheearlystagesofboneformation,asitinhibitshormone-stimulatedmodulationofERand1-OHaseexpressionaswellasDNAsynthesis,creatinekinaseactivity,andalkalinephosphataseactivity.
| CasNo. | 366789-02-8 |
|---|---|
| Purity | ≥98% |
| Formula | C19H18ClN3O5S |
| FormulaWt. | 435.88 |
| IUPACName | 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide |
| Solubility | MeOH |
| Appearance | Whitetooffwhitepowder |
| StoreTemp | Ambient |
|---|---|
| ShipTemp | Ambient |
| MSDS | R3584MSDSPDF |
|---|---|
| InfoSheet | R3584InfoSheetPDF |
KreutzR.PharmacokineticsandPharmacodynamicsofRivaroxaban-AnOral,DirectFactorXaInhibitor.CurrClinPharmacol.2013Nov11.[Epubaheadofprint].PMID:24218999.
SomjenD,KatzburgS,GigiR,etal.Rivaroxaban,adirectinhibitorofthecoagulationfactorXainterfereswithhormonal-inducedphysiologicalmodulationsinhumanfemaleosteoblasticcelllineSaSO2.JSteroidBiochemMolBiol.2013May;135:67-70.PMID:23333933
GigiR,SalaiM,DolkartO,etal.TheeffectsofdirectfactorXainhibitor(Rivaroxaban)onthehumanosteoblasticcelllineSaOS2.ConnectTissueRes.2012;53(6):446-50.PMID:22800431.
SamamaMM.Themechanismofactionofrivaroxaban--anoral,directFactorXainhibitor--comparedwithotheranticoagulants.ThrombRes.2011Jun;127(6):497-504.PMID:20888031.
